REVIEW PAPER<br>The role of tocilizumab in the treatment of rheumatoid arthritis

Aleksandra Tuchocka; Mariusz Puszczewicz

eISSN: 2084-9834
ISSN: 0034-6233

Reumatologia/Rheumatology

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2008
vol. 46

Send email

Copy url:

abstract:

REVIEW PAPER
The role of tocilizumab in the treatment of rheumatoid arthritis

Aleksandra Tuchocka

,

Mariusz Puszczewicz

Reumatologia 2008; 46, 3: 140–150

Online publish date: 2008/07/09

View full text Get citation

Interleukin 6 (IL-6) is a pleiotropic cytokine displaying multiple biological activities. Dysregulation of IL-6 appears to contribute to both systemic and local rheumatoid arthritis (RA) symptoms. Tocilizumab is a neutralising antibody to suppress IL-6 signalling mediated by both membranous and soluble IL-6-receptor. Clinical efficacy and safety of tocilizumab in RA are discussed in this review. According to data available so far tocilizumab has proved its ability to reduce disease activity, suggesting that IL-6 plays an essential role in the pathogenesis of this chronic autoimmunological inflammatory process.

keywords:

tocilizumab, interleukin 6, rheumatoid arthritis

EVENTS/KONFERENCJE

BOOKS/KSIĄŻKI

REVIEW PAPERThe role of tocilizumab in the treatment of rheumatoid arthritis

Aleksandra Tuchocka , Mariusz Puszczewicz

tocilizumab, interleukin 6, rheumatoid arthritis

REVIEW PAPER
The role of tocilizumab in the treatment of rheumatoid arthritis

Aleksandra Tuchocka

,

Mariusz Puszczewicz